Literature DB >> 2784674

Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells.

J Pfeilschifter1, W Pignat, K Vosbeck, F Märki.   

Abstract

Treatment of rat glomerular mesangial cells with recombinant human interleukin 1 alpha (rIL-1 alpha), recombinant human interleukin 1 beta (rIL-1 beta) or recombinant human tumor necrosis factor (rTNF) induces prostaglandin E2 (PGE2) synthesis and the release of a phospholipase A2 (PLA2) activity. rIL-1 beta is significantly more potent than rIL-1 alpha or rTNF in stimulating PGE2 as well as PLA2 release from mesangial cells. When given together, rTNF interacts in a synergistic fashion with rIL-1 alpha and rIL-1 beta to enhance both, PGE2 synthesis and PLA2 release. The released PLA2 has a neutral pH optimum and is calcium-dependent. Pretreatment of cells with actinomycin D or cycloheximide inhibits basal and cytokine-stimulated PGE2 and PLA2 release.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2784674     DOI： 10.1016/0006-291x(89)90003-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  40 in total

Review 1.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 2.  The role of inflammation as a pathogenic factor in the development of renal disease in diabetes.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

3.  Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; S Tarui; M Okamoto
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 4.  Inflammation in diabetic kidney disease.

Authors:  Patricia M García-García; María A Getino-Melián; Virginia Domínguez-Pimentel; Juan F Navarro-González
Journal:  World J Diabetes       Date:  2014-08-15

5.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

6.  Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells.

Authors:  J Pfeilschifter; J Leighton; W Pignat; F Märki; K Vosbeck
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

7.  Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A2 in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor.

Authors:  X Sun; M S Caplan; W Hsueh
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Human cytomegalovirus-induced immunosuppression. Relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E2 in human monocytes.

Authors:  M A Nokta; M I Hassan; K Loesch; R B Pollard
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Longitudinal changes in tear fluid lipidome brought about by eyelid-warming treatment in a cohort of meibomian gland dysfunction.

Authors:  Sin Man Lam; Louis Tong; Xinrui Duan; U Rajendra Acharya; Jen Hong Tan; Andrea Petznick; Markus R Wenk; Guanghou Shui
Journal:  J Lipid Res       Date:  2014-07-03       Impact factor: 5.922

10.  Differential inhibition of human secretory and cytosolic phospholipase A2.

Authors:  F Märki; W Breitenstein; E Beriger; R Bernasconi; G Caravatti; J E Francis; R Paioni; H U Wehrli; R Wiederkehr
Journal:  Agents Actions       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.